Guselkumab May Have Edge Over Secukinumab in Long-Term Control of Psoriasis Guselkumab May Have Edge Over Secukinumab in Long-Term Control of Psoriasis

For moderate-to-severe plaque psoriasis, treatment with guselkumab was superior to secukinumab based on 90% or better improvement from baseline in patients ' Psoriasis Area and Severity Index score (PASI 90) at 48 weeks in the ECLIPSE study.Reuters Health Information

Source: Medscape Medical News Headlines - August 18, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news